Major International FDA-led study confirms CellOPTIQ® High Content Assay as the Leading In Vitro platform to Assess Cardiotoxicity in New Drugs
September 27, 2018
Motherwell, Scotland, 27th September 2018 – Clyde Biosciences, the leader in cardiac cell function assessment, announced today that its proprietary CellOPTIQ® High Content Assay (HCA)